LOGIN OR REGISTER
Course Library

Psoriatic Arthritis: Understanding the Patient Experience to Improve Patient Satisfaction and Outcomes

Rheumatology
Curriculum:
Understanding the Patient Experience to Improve Patient Satisfaction and Outcomes
Credits:
0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 27, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Rheumatologists; dermatologists; and other clinicians that care for patients with PsA including rheumatology and dermatology NPs and PAs

Relevant Terms:

Psoriasis; psoriatic arthritis

Alan Menter, MD

Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas, Southwestern Medical School
Dallas, TX

Dr. Menter has a long-held interest in psoriasis and psoriatic disease research. He co-authored the first gene discovery for psoriasis, published in Science in 1994. His research on psoriasis has examined everything from ultraviolet phototherapy, biologic therapy to the mapping of genetic patterns to predict if a person is at risk of developing psoriasis.
 
In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,600 patients on systemic and biologic therapy and phototherapy.

Daniel Furst, MD

Daniel Furst, MD
Carl M. Pearson Professor of Medicine
Director, Rheumatology Clinical Research Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

Dr. Furst is the first Carl M. Pearson Professor in Rheumatology. He has been on a number of national committees concerned with rheumatic therapeutics, including as a member and Fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the FDA. He currently serves as Chairman of the Innovative Therapies Meeting of the American College of Rheumatology and Clinical Abstracts Selection Chair for the National American College of Rheumatology meeting and Chairman of the Standing Committee on Clinical Trials for the International League Against Rheumatism. He has served or is serving on the editorial boards of Inpharma, Clinical Drug Investigation, Drugs, The Journal of Clinical Rheumatology, and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, The New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy, Annals of the Rheumatic Diseases, and The Journal of Rheumatology. Dr. Furst has published more than 400 articles and 12 books, including more than 180 research articles and more than 210 reviews or chapters in addition to two editions of a book on scleroderma. Dr. Furst's areas of research interest include RA, scleroderma and polymyosistis/dermatomyositis.
1. Describe issues that patients consider as having an impact on disease severity that are not incorporated into current evaluation instruments
2. Discuss how patient beliefs about and perception of PsA affect willingness to participate in the creation of and adherence to management strategies
3. Discuss the factors that contribute to the divergence of satisfaction ratings between clinicians and patients
4. Demonstrate communication techniques to best engage patients with PsA so they can participate in an informed manner in developing management plans based on their individual clinical and psychosocial needs

DISCLOSURES
Alan Menter, MD, discloses the following relationships with commercial interests: 
Advisory board: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Janssen Biotech, Inc., LEO Pharma, Lilly
Consultant: AbbVie, Allergan, Amgen, Galderma, Janssen Biotech, Inc., LEO Pharma, Lilly, Novartis, Pfizer, Vitae, Xenoport
Investigator: AbbVie, Allergan, Amgen, Anacor, Boehringer Ingelheim, Celgene, Dermira,  Janssen Biotech, Inc., LEO Pharma, Lilly, Merck, Neothetics, Novartis, Pfizer, Regeneron, Symbio/Maruho, Xenoport
Speakers bureau: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma

Daniel Furst, MD, discloses the following relationships with commercial interests: 
Consultant: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Genentech, Novartis, Pfizer, Roche
Investigator:  AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Corbus, Genentech, Novartis, Pfizer, Roche

Penn State staff involved in the development and review of this activity have nothing to disclose.
Joshua Kilbridge, Medical Writer, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose. 
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education has no conflicts of interest to disclose. 
 
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
 
Credit is awarded to participants who score 65% or better on the post-test. 
The online activity will take approximately 45 minutes to complete.

CREDIT STATEMENTS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. 
 
Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6074-17-T.

COMMERCIAL SUPPORT STATEMENT
This activity is supported by an educational grant from Pfizer.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


 

DISCLAIMER
© 2017 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.

Schedule an event with a Standardized Patient
×